(firstQuint)Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis.

 A phase II, randomized, double-blind, placebo-controlled study to: 1.

 Demonstrate the clinical efficacy of efalizumab in the treatment of subjects with psoriatic arthritis (PsA).

 2.

 Evaluate the safety, tolerability and pharmacokinetics of efalizumab in the treatment of subjects with PsA.

 Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis@highlight

The purpose of this study is to determine whether a humanized monoclonal antibody (efalizumab) is safe and effective in the treatment of psoriatic arthritis (PsA)